Baxter International Inc $ 76.42 -0.73 (-0.95%)
Volume:
3,917,725
Avg Vol (1m):
2,900,209
Market Cap $:
38.60 Bil
Enterprise Value $:
41.71 Bil
PE Ratio:
35.71
PB Ratio:
4.54
Current and historical daily P/E ratio for BAX (Baxter International Inc) from 1990 to Mar 04 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Baxter International stock (BAX) PE ratio as of Mar 04 2021 is 35.71.
More Details
Baxter International PE Ratio (TTM) Chart
EMBED
Baxter International PE Ratio (TTM) Historical Data
View and export this data going back to 1990. Start your Free Trial
Total 1245
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Baxter International PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2021-03-05 | 35.7 | 2020-12-30 | 37.0 |
| 2021-03-04 | 35.7 | 2020-12-29 | 37.4 |
| 2021-03-03 | 36.1 | 2020-12-28 | 37.0 |
| 2021-03-02 | 36.3 | 2020-12-24 | 45.0 |
| 2021-03-01 | 36.4 | 2020-12-23 | 44.5 |
| 2021-02-26 | 36.3 | 2020-12-22 | 44.4 |
| 2021-02-25 | 36.8 | 2020-12-21 | 44.7 |
| 2021-02-24 | 36.7 | 2020-12-18 | 45.7 |
| 2021-02-23 | 36.5 | 2020-12-17 | 45.8 |
| 2021-02-22 | 36.9 | 2020-12-16 | 45.2 |
| 2021-02-19 | 36.7 | 2020-12-15 | 45.0 |
| 2021-02-18 | 36.8 | 2020-12-14 | 44.5 |
| 2021-02-17 | 36.3 | 2020-12-11 | 44.8 |
| 2021-02-16 | 36.4 | 2020-12-10 | 44.7 |
| 2021-02-15 | 36.8 | 2020-12-09 | 44.8 |
| 2021-02-12 | 36.8 | 2020-12-08 | 44.0 |
| 2021-02-11 | 36.4 | 2020-12-07 | 43.9 |
| 2021-02-10 | 36.3 | 2020-12-04 | 44.1 |
| 2021-02-09 | 36.0 | 2020-12-03 | 43.1 |
| 2021-02-08 | 36.3 | 2020-12-02 | 43.1 |
| 2021-02-05 | 36.1 | 2020-12-01 | 42.7 |
| 2021-02-04 | 36.1 | 2020-11-30 | 43.0 |
| 2021-02-03 | 36.1 | 2020-11-27 | 42.9 |
| 2021-02-02 | 35.8 | 2020-11-25 | 42.6 |
| 2021-02-01 | 35.7 | 2020-11-24 | 43.0 |
| 2021-01-29 | 35.9 | 2020-11-23 | 42.8 |
| 2021-01-28 | 36.1 | 2020-11-20 | 43.5 |
| 2021-01-27 | 36.5 | 2020-11-19 | 44.6 |
| 2021-01-26 | 37.8 | 2020-11-18 | 45.4 |
| 2021-01-25 | 37.4 | 2020-11-17 | 45.6 |
| 2021-01-22 | 37.2 | 2020-11-16 | 45.8 |
| 2021-01-21 | 37.4 | 2020-11-13 | 46.5 |
| 2021-01-20 | 37.2 | 2020-11-12 | 46.1 |
| 2021-01-19 | 36.8 | 2020-11-11 | 45.7 |
| 2021-01-15 | 37.4 | 2020-11-10 | 46.1 |
| 2021-01-14 | 37.4 | 2020-11-09 | 45.8 |
| 2021-01-13 | 38.5 | 2020-11-06 | 44.6 |
| 2021-01-12 | 37.6 | 2020-11-05 | 43.9 |
| 2021-01-11 | 38.5 | 2020-11-04 | 42.8 |
| 2021-01-08 | 38.2 | 2020-11-03 | 43.7 |
| 2021-01-07 | 38.1 | 2020-11-02 | 44.5 |
| 2021-01-06 | 37.8 | 2020-10-30 | 43.8 |
| 2021-01-05 | 38.0 | 2020-10-29 | 44.1 |
| 2021-01-04 | 37.4 | 2020-10-28 | 44.2 |
| 2020-12-31 | 37.5 | 2020-10-27 | 45.6 |
Baxter International PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Compare
NYSE:RMD
NAS:ISRG
NYSE:BDX
NYSE:TFX
NYSE:WST
NYSE:COO
NAS:HOLX
NYSE:STE
NAS:MASI
NYSE:VAR
XPAR:EL
OCSE:COLO B
TSE:7741
XSWX:ALC
TSE:4543
XPAR:DIM
XTER:SRT
TSE:7733
XSWX:SOON
XSWX:STMN
Traded in other countries
BAX.Austria
B1AX34.Brazil
BTL.Germany
BAX.Mexico
BAX.Switzerland
0QK8.UK
BAX.USA
Address
One Baxter Parkway, Deerfield, IL, USA, 60015
Baxter manufactures medical products across seven major reported business segments. The renal segment (32% of 2019 sales) includes peritoneal dialysis and hemodialysis products for chronically ill patients while its acute therapies segment (5%) offers kidney or other organ support tools in intensive care situations. The medication delivery segment (25% of sales) sells IV pumps, administrative sets, and solutions while its nutrition segment (8% of sales) offers parenteral nutrition therapies. The pharmaceuticals segment (19% of sales) offers injectable drugs, anesthetic gases, and compounding services. The advanced surgery segment (8% of sales) provides hemostastic products and biosurgical sealants. Contract manufacturing rounds out the remaining sales.